Market Overview

TerrAscend Reports Q2 Revenue Growth, Raises Guidance

Share:
TerrAscend Reports Q2 Revenue Growth, Raises Guidance
Read more about our latest Cannabis News! CANNABIS HOME

TerrAscend Corp. (CSE: TER) (OTC: TRSSF) reported second-quarter revenue of CA $17.6 million, up 21% from CA $14.6 million in the first quarter.

Its non-GAAP adjusted EBITDA was (CA $12.5 million) for the second quarter, versus (CA $6.4 million) in the first quarter.

TerrAscend also raised guidance, expecting to reach a revenue of more than CA $141 million in 2019, up from CA $135 million previously announced in April.

Click here more information about the upcoming Benzinga Cannabis Capital Conference Oct. 22-23 in Chicago.

"The Company continues to experience strong growth in demand. We are pleased to be in the position to raise our revenue guidance only four months after initially providing it. We are seeing a substantial acceleration in sales growth in the third quarter and expect this to continue through the fourth quarter,” said CEO Michael Nashat.

TerrAscend President Matthew Johnson said the company works on further expanding.

"TerrAscend continues to increase its global footprint with the build-out of our New Jersey operations, construction of multiple dispensaries in California, and the upcoming acquisition of Ilera Healthcare. We are looking forward to opening new dispensaries in California, Pennsylvania and New Jersey in the coming months,” said Johnson.

The stock traded down 2.7% at $4.80 per share at time of publication.

Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.

Read more about our latest Cannabis News! CANNABIS HOME

Posted-In: Michael NashatCannabis Earnings News Guidance Markets

 

Related Articles (TRSSF)

View Comments and Join the Discussion!

Cannabis Movers

Sign up for our secret cannabis newsletter!
Never miss out on the breaking news in the Cannabis Industry!

Calm Before Storm? Powell Friday Speech Awaited After Brief Yield Curve Inversion

Thursday's Market Minute: Right On Target